Personalis Announces Publication Validating NeXT Personal Test For Ultra-Sensitive MRD Detection And Cancer Treatment Response Monitoring
Portfolio Pulse from Benzinga Newsdesk
Personalis, Inc. (NASDAQ:PSNL) announced the validation of its NeXT Personal test, an ultra-sensitive assay for detecting minimal residual disease (MRD) and monitoring cancer treatment response. The test, which uses a personalized tumor-informed approach, demonstrated high analytical sensitivity and accuracy across nine cancer types in a study. Initial findings at the ESMO Congress showed its potential clinical benefit in early-stage lung cancer detection and outcome prediction.
March 26, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Personalis, Inc. announced the validation of its NeXT Personal test, showcasing its potential in early cancer detection and treatment monitoring, which could lead to Medicare coverage.
The validation of the NeXT Personal test by Personalis, Inc. represents a significant advancement in precision oncology, potentially improving patient outcomes and opening pathways to Medicare coverage. This development is likely to be viewed positively by investors, given the test's demonstrated high sensitivity and accuracy, along with its potential to enhance cancer treatment decision-making. The mention of potential clinical benefits in early-stage lung cancer further underscores the test's significance and could lead to increased interest and investment in PSNL.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100